Validation of the Hebrew version of the International Parkinson and Movement Disorder Society—unified Parkinson’s disease rating scale (MDS-UPDRS)
Objective: To assess the clinimetric properties of the Hebrew version of the MDS-UPDRS. Background: The Unified Parkinson's disease Rating Scale (UPDRS) is a rating scale…J-FIRST: First-in-Japan observational study of Parkinson’s disease treatments and nonmotor symptoms
Objective: To clarify the clinical manifestations of nonmotor symptoms (NMSs) and identify factors affecting NMSs and quality of life (QOL) in Japanese patients with Parkinson's…Impulse control disorders after STN DBS for Parkinson’s disease
Objective: To evaluate the prevalence and severity of impulse control disorders (ICD) and other impulsive-compulsive behaviors (ICB) in a cohort of patients with Parkinson's disease…Diagnostic sensitivity and remote monitoring of motor and non-motor dysfunction in Parkinson’s disease
Objective: To determine if 24-hour tri-axial accelerometer and heart rate measurements can (1) discriminate Parkinson's disease (PD) from healthy controls and (2) monitor severity of…Empowering Parkinson’s patients to declare pain: A multicenter report of the use of the first Parkinson’s pain questionaire (King’s PD pain quest)
Objective: To report the use of the first and easy to use self-completed Parkinson's specific pain questionnaire (King's PD Pain Quest (KPPQ), which is complementary…Non-motor symptoms in a PPMI cohort of p.A53T α-synuclein mutation-related and sporadic Parkinson’s disease patients
Objective: To evaluate the prevalence of non-motor symptoms in p.A53T α-synuclein (SNCA) related Parkinson's disease (PD) as compared to sporadic Parkinson's disease (sPD) patients. Background:…Analysis of the olfactory impairments in PINK1 deficient mice
Objective: To explore the olfactory effect of PINK1 deficiency in serotonergic and dopaminergic neurons we did a behavioral analysis of young mice, deficient for PINK1…Substantial motor and non-motor symptoms in children and adults with classical galactosemia and organic acidurias
Objective: To investigate the prevalence of movement disorders (MDs), their impact on quality of life (QoL) and accompanying non-motor symptoms in patients with classical galactosemia…The International Parkinson and Movement Disorder Society – non-motor rating scale (MDS-NMS): Results from the cognitive pre-testing and phases 1 and 2 of an international validation
Objective: To revise the Non-Motor Sumptom Scale (NMSS) and develop a new up to date version, the MDS-NMS, a project commissioned by the International Parkinson…Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson’s disease: A prospective study
Objective: The aim of the present study was to determine the effects of istradefylline, adenosine A2A receptor antagonist on lower urinary tract symptoms (LUTS) in…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.